News

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

The professor of neurology at NYU Langone gives her input on those who are nervous to take hospital trips, as well as the protocol for patients with neurological disorders as COVID-19 slows down.

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

The neurologist at the Barrow Neurological Institute discussed how to best address telemedicine appointments and exams for patients who may be at risk for a fall or some other safety concern.

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

The trio of authors from Johns Hopkins discussed the findings of a study that imply that BMI is associated with accelerated rates of ganglion cell and inner plexiform layer atrophy in those with multiple sclerosis.

Women with migraine with cold extremities had higher attack frequencies, which data suggest stems partly from sleep disturbances.

The clinical neurology fellow at Brigham and Women's Hospital and Harvard University detailed what recent survey data suggest, why the survey was conducted, and how to possibly improve the approach to the protocol.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 8, 2020.

The wide variance in onabotunlinumtoxinA use for migraine prevention raises the question of whether evidence-based advisory statements might be more helpful than a proscriptive protocol.

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.

An identified association between accelerated rates of ganglion cell and inner plexiform layer atrophy in the absence of overt metabolic comorbidities suggests that obesity may affect accelerated neurodegeneration in those with multiple sclerosis.

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.

Data showed that Ovid Therapeutics’ gaboxadol, also known as OV101, was well-tolerated and had a significant effect on secondary behavioral end points in the 3 combined study groups.

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic details the rampant acceleration of telemedicine and how her practice is adjusting to the COVID-19 pandemic.

The first study to assess the effect of endovascular therapy added on to intravenous thrombolysis uncovered more evidence of its effect on specific occlusions rather than overall outcomes.

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation detailed what he foresees the future of Alzheimer and dementia care to look like with telemedicine as a more permanent aspect of care.

The positron emission tomography tau tracer was shown to identify high levels of Alzheimer disease neuropathologic change and neurofibrillary tangles with good sensitivity and specificity.

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.

Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.

The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications.

The case-based reports ultimately suggest that more data collection is required, but highlight the observations of more than 60 patients, including a 5-patient cohort with Guillain-Barré syndrome.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine detailed the advancements that have been made with OSA treatment devices.

Data led the authors to believe that vitamin D might have neuroprotective properties and that levels may be a prognostic marker of long-term cognition and neuroaxonal integrity.

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.